Immuneering Plans To Initiate Phase 2 Clinical Trial Evaluating Atebimetinib In Combination With Chemotherapy In Patients With Anaplastic Thyroid Cancer
Benzinga Newsdesk 5 hours ago
News
- Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic thyroid cancer (ATC), a highly aggressive cancer with significant unmet need commonly
- Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic thyroid cancer (ATC), a highly aggressive cancer with significant unmet need commonly driven by BRAF or RAS mutations -
- IND submission planned by year-end 2026, with first patient dosing targeted for mid-2027; study is designed to be potentially registrational -
- Preclinical data supporting the rationale for atebimetinib + chemotherapy in ATC to be presented at the 38th EORTC-NCI-AACR Symposium on November 18, 2026 –
- Aligns with Immuneering’s strategy to provide a broad population of cancer patients with important new treatment options –
- Company to hold investor webcast today at 8:30am EST, to discuss both of today’s news announcements; including its clinical development plans in anaplastic thyroid cancer and the collaboration to evaluate CLDN18.2 programs in combination with atebimetinib for pancreatic cancer -
NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced plans to initiate a Phase 2 clinical trial evaluating atebimetinib in combination with chemotherapy in patients with anaplastic thyroid cancer (ATC), a highly aggressive form of thyroid cancer with significant unmet need, commonly driven by BRAF or RAS mutations.
Immuneering plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the program by the end of 2026. Subject to regulatory clearance, Immuneering currently expects to dose the first patient in the study in mid-2027, with topline results potentially available 12-18 months after dosing begins. The preliminary study plan is to enroll approximately 60 patients with ATC who progressed on standard of care, including an all-comers cohort and a BRAF V600E cohort. The study is designed to be potentially registrational, pending discussion with regulators.